Inflammatix

Company profile

About Inflammatix

Inflammatix is a molecular diagnostics company that has developed a first-in-class approach to diagnosing acute infections and sepsis by 'reading' the immune system's response rather than targeting pathogens directly. The company's flagship product, TriVerity, is an FDA-cleared diagnostic test designed for emergency department use that provides three actionable scores: likelihood of bacterial infection, likelihood of viral infection, and all-cause illness severity (defined as risk of progression to mechanical ventilation, vasopressors, or renal replacement therapy within seven days). The company's technology is powered by measuring mRNA profiles from immune cells in whole blood, combined with machine learning and artificial intelligence to interpret these host response signatures. This approach addresses a critical limitation of traditional pathogen-targeting tests, which are often insensitive because most infections remain locally contained and don't penetrate the bloodstream. Inflammatix's immune cells circulate into the blood after fighting infections locally, allowing their signatures to be measured and analyzed. Inflammatix leverages expertise in bioinformatics, molecular biology, and machine learning to develop diagnostics that help physicians make confident and timely clinical decisions in emergency settings where time, space, and certainty are in short supply. The company's mission centers on empowering emergency clinicians to rapidly recognize and act early on acute infections with unparalleled precision, transforming triage through early actionability, prognostic clarity, and exceptional accuracy that has been clinically proven to exceed standard of care.

Company description · Inflammatix official website